Loading quotes...
Forecast
The analysts' average price target is €91.92 (+4.48%). The median is €92.72 (+5.39%).
| Buy |
17 |
| Hold |
22 |
| Sell |
3 |
News Go to news feed
Zimmer Biomet reduces job cuts in Winterthur and delays implementation until 2030
At the Winterthur site, Zimmer Biomet will cut up to 490 jobs instead of up to 580 and will spread the reductions over a longer period. Certain production activities will be shifted to other locations, while the DynaForge forge and the manufacture of certain hip components will remain in Winterthur. Research, development and support functions will stay at the site; there will be no layoffs before 2028 and the social plan has been extended until 2030. Switzerland remains an important EMEA location for the group. » More on finanzen.net
Zimmer Biomet plans to cut up to 580 jobs in Winterthur
The US medical device company Zimmer Biomet announced that as part of a production restructuring it may cut up to 580 of the 730 jobs in Winterthur. A consultation procedure has been started; the cuts have not yet been finally decided. The company emphasizes the importance of the site and its employees but points to the planned changes. » More on finanzen.net
Zimmer Biomet announces quarterly dividend of $0.24
The board of Zimmer Biomet has approved a quarterly cash dividend of $0.24 per share for the third quarter of 2026. Payment will be made on October 30, 2026 to shareholders of record at the close of business on September 30, 2026. The company operates in the medical technology sector and distributes products in more than 100 countries. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 1.91bn | 8.23% |
| Gross profit | 1.35bn | 7.20% |
| Net profit | 173.75m | 34.03% |
| EBITDA | 524.67m | 7.42% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €16.76bn |
Number of shares | 190.74m |
52-week high/low | €92.85 - €70.54 |
Dividend yield | 0.93% |
Dividends TTM | €0.82 |
Next dividend | €0.21 |
Beta | 0.49 |
P/E ratio | 23.86 |
PEG ratio | 98.32 |
P/B ratio | 1.50 |
P/S ratio | 2.21 |
Company profile
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest toss facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as robotic, surgical and bone cement products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
| Name | Zimmer Biomet |
| CEO | Ivan Tornos |
| Headquarters | Warsaw,
in USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 25/07/2001 |
| Employees | 17,000 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NYSE | ZBH |
SIX | ZBH.SW |
Frankfurt | ZIM.F |
Düsseldorf | ZIM.DU |
London | 0QQD.L |
München | ZIM.MU |
Wien | ZBH.VI |
Milan | 1ZBH.MI |